Leerink Partners analyst Mani Foroohar maintained a Hold rating on Alnylam Pharmaceuticals on Monday, setting a price target of $104, which is approximately 39.90% below the present share price of $173.05.
Foroohar expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.72 for the fourth quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $197.12.
The analysts price targets range from a high of $275 to a low of $108.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $187.63 million and a net profit of -$181.68 million. The company's market cap is $20.7 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 35.04% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.